In addition, risk factors for hepatocarcinogenesis after an SVR in patients who receive IFN-based therapy include older age, advanced liver fibrosis, male sex, the AFP level after treatment, glucose metabolism disorders, lipid metabolism disorders and alcohol intake, and other factors [17, 22, 32]. Here, AFP is linked to glucose metabolism disease.